Our scientific goal is to provide, via organic chemistry and synthesis, small molecules as druggable candidates and chemical tools for a better understanding of biological processes in the field of cancer. The discovery of new molecules interacting with living organisms benefits from the team’s expertise in modeling and molecular dynamics.
In parallel with these drug discovery projects, we are continuing to develop and optimize methods in organic chemistry in order to introduce molecular diversity and open new chemical space and on normal modes in order to implement…
Thanks to the drug discovery expertise acquired through the collaboration with the biotech Abivax and through the development of ATP competitive kinase inhibitors, the team is developing medicinal chemistry on innovative projects in oncology in collaboration with biologists from Institut Curie. Our research focusses on non-ATP competitive inhibitors of kinase of the TAM family and on a receptor coupled to protein G identified as a potential target of melanoma. For these goals, the screening of the Curie-CNRS chemistry library is an asset to identify hits that require further hit-to-lead optimization.
The questions of subcellular detection, localization and quantification in cellular medium of small molecules are crucial in their development as chemical tools or as drugs. Therefore, we also pursue our efforts on development of new fluorophores for cellular subcompartments labelling as well as biosensors for protein labeling.
|
Internal motions of a microtubule doublet. Flagellar microtubule doublet (MTD) assembly in vitro reveals a regulatory role of tubulin C-terminal tails. In support of the in vitroexperiments, we performed molecular simulations that showed that all MTD tails are not equivalent in this regulation (Science 363, 285-288 (2019)). In the movie presented here, we display four essential motions of MTD in the absence of the tubulin tails. These motions correspond to the four lowest-frequency normal modes. |
